Singapore AI startup K25.ai raises $4m from NewGenIVF in extended funding round

Singapore-based AI startup K25.ai has secured an additional $4 million from NewGenIVF Group, extending its funding round as part of a broader wave of early-stage AI deals across Southeast Asia. The investment comes through a deal-monitor update that also tracked fresh capital for other regional startups, signalling continued investor appetite for applied AI ventures despite a tighter funding environment.

K25.ai operates in the AI applications space, though specific product details remain limited in public disclosures. NewGenIVF Group, primarily known for fertility and healthcare services, appears to be diversifying into AI-enabled healthtech — a logical adjacency where AI can accelerate diagnostics, treatment planning, and operational efficiency. The follow-on investment suggests the investor sees traction since its initial commitment.

Southeast Asia's AI funding landscape remains fragmented but active, with Singapore continuing to attract the lion's share of early-stage capital. DealStreetAsia's latest deal monitor also noted funding for fellow Singapore AI startup FORMAS.AI ($3.98 million) in late April, alongside deals in Indonesia, Vietnam, and Malaysia. The pattern points to a growing cohort of Singapore-origin AI companies reaching Series A and extension rounds, even as later-stage funding tightens globally.

Why it matters for Singapore: K25.ai adds to the pipeline of homegrown AI startups raising institutional capital in Singapore. Each successful funding round reinforces the ecosystem's ability to nurture applied AI ventures from research to commercialization. With NewGenIVF's healthcare background, this deal also hints at the cross-sector AI adoption — healthtech, fintech, logistics — that Singapore's national AI strategy aims to catalyse across the economy.